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REPLY
In our recent editorial (1) we commented on the expression and
activity of the NAD(P)H oxidase subunit gp91phox isoform in the
failing human heart reported by Heymes et al. (2). We also stated
that this evidence was provided for the first time, not mentioning
the article by Krijnen et al. (3), which was published in the March
issue of the Journal of Clinical Pathology. One simple reason for that
was that our editorial comment was already in press when the
report from Krijnen et al. appeared. In that study the investigators
describe the existence of Nox 2 (gp91phox) in normal human
cardiomyocytes and an up-regulation of the expression as assessed
by Western blotting technique and by immunohistochemistry in
viable and jeopardized cardiomyocytes of freshly infarcted areas.
Since this report was published in March, we agree that the study
was indeed the first to comment on the expression of the
NAD(P)H oxidase subunit Nox2 in human cardiomyocytes. Al-
though the researchers have observed an increase in Nox2 in
myocardial areas subject to acute myocardial infarction (AMI), one
cannot really compare this situation with that of chronic congestive
heart failure. Acute myocardial infarction is always accompanied
by an acute and severe inflammatory response, and in the studies by
Krijnen et al. no data were provided as to whether these patients
had clinical signs of acute heart failure. Thus, the correspondent
may agree that Heymes et al. (2) provided the first evidence for a
lack of changes in the expression of Nox2 but an increase in the
activity of the enzyme in patients with severe chronic congestive
heart failure.
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We thank Dr. Krijnen and colleagues for their interest in our
report (1). The data, presented at the American Heart Association
scientific sessions in 2002 (2), build upon prior experimental
studies from our group and others (see Ref. 1). Although Krijnen
et al. (3) discuss some parallels between our study and their recent
interesting publication, several important differences should be
emphasized.
The NAD(P)H oxidase is a multisubunit complex that requires
not only a core catalytic Nox subunit but also several other
components (p22phox, p47phox, p40phox, rac) for its function (4).
Clear evidence of NAD(P)H oxidase expression and activity
requires both the demonstration of multiple subunits and evidence
of biochemical activity, as provided in our report (1). In addition,
analysis of expression based solely on immunoblotting or immu-
nohistochemistry is complicated by the fact that several Nox
isoforms have recently been reported (4). Ideally, antibody-based
methods should be complemented by RNA-based analyses (1).
The best approach in experimental studies may be to employ
gene-modified models (5).
With respect to NAD(P)H oxidase activation, this is recognized
to occur through posttranslational modifications of one or more
subunits (e.g., phosphorylation of p47phox) and/or altered expres-
sion levels (4). In our opinion, comments on mechanisms of
activation of this complex enzyme based solely on qualitative
analyses of Nox2 by immunohistochemistry are probably unwar-
ranted. Our study found no change in overall tissue expression level
of the four main oxidase subunits in end-stage chronic heart
failure, whereas immunofluorescence studies indicated a translo-
cation of p47phox to the cardiomyocyte sarcolemma where
gp91phox was also present (1). Nevertheless, activation mechanisms
of the oxidase remain speculative.
Finally, the condition we studied (chronic nonischemic conges-
tive heart failure) (1) is quite distinct from the focus of Krijnen’s
report (acute myocardial infarction) (3). The NADPH oxidase
subunit expression, cellular localization, stimuli for activation, and
activation mechanisms could well be significantly different among
these conditions.
Ajay M. Shah, MD, FRCP, FAHA
Department of Cardiology
GKT School of Medicine
Bessemer Road
London SE5 9PJ
United Kingdom
E-mail: ajay.shah@kcl.ac.uk
Christophe Heymes, PhD
doi:10.1016/j.jacc.2003.10.003
REFERENCES
1. Heymes C, Bendall JK, Ratajczak P, et al. Increased myocardial
NADPH oxidase activity in human heart failure. J Am Coll Cardiol
2003;41:2164–71.
2. Heymes C, Bendall JK, Ratajczak P, et al. Increased NADPH oxidase-
mediated superoxide production in human heart failure: potential role in
left ventricular dysfunction (abstr). Circulation 2002;106:II202.
3. Krijnen PAJ, Meischl C, Hack CE, et al. Increased Nox2 expression in
human cardiomyocytes after acute myocardial infarction. J Clin Pathol
2003;56:194–9.
2171JACC Vol. 42, No. 12, 2003 Letters to the Editor
December 17, 2003:2167–73
